C-H (Synthetics Pre-2010)

SYNTHETICS and COMPOUNDS THAT AFFECT the ENDOCANNABINOID SYSTEM Pre-2010

CANNABINOR (CB2 Agonist)
CP-47,497 (CB1 and CB2 Agonist [1982-2009])
CP-50,556-1 / LEVONANTRADOL (CB1 and CB2 Agonist [1983-2001])
CP-55,940 (CB1, CB2 and GPR55 Agonist [1991-2009])
CRA-13 (CB1 and CB2 Agonist [2007-2009])
DRONABINOL (See MARINOL)
ELMIRIC ACIDS (Anandamide Analogs)
GW-405833
GW-833972A (Strong CB2 Agonist)
HEXAHYDROCANNABINOLS
HU-210 (CB1 and CB2 Agonist Over 100 Times Stronger Than THC [1999-2009])
HU-211 / DEXANABINOL / DEXANABINONE / SINNABIDOL / ETS-2101 / PA 50211 / PRS 211007 (CB2 Agonist [1993-2009])
HU-308 (CB2 Agonist [1999-2008])
HU-310 (CB1 Agonist)
HU-320 (Chemically Related to CBD, Mechanism Of Action Not Established)
HU-331 (Derived From CBD, Mechanism Of Action Not Established)


CANNABINOR
Pharmos Initiates Phase I Trial of CB2-Selective Drug Candidate Cannabinor (news–2005) http://www.prnewswire.com/news-releases/pharmos-initiates-phase-i-trial-of-cb2-selective-drug-candidate-cannabinor-54718747.html
Cannabinoid Receptor Agonist Significantly Reduces Post-Operative Pain, Study Says (news–2007) http://norml.org/index.cfm?Group_ID=7246
Patent application title: Treatment Of Lower Urinary Tract Dysfunction With CB2-Receptor-Selective Agonists (full–2009) http://www.faqs.org/patents/app/20090312414
top


CP-47,497
Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol (abst–1982) http://jpet.aspetjournals.org/content/223/2/516.abstract?maxtoshow=&hits=80&RESULTFORMAT=&fulltext=Hexahydrocannabinol&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT
The Conformational Properties of the Highly Selective Cannabinoid Receptor Ligand CP-55,940 (full–1996) http://www.jbc.org/content/271/18/10640.full?maxtoshow=&hits=80&RESULTFORMAT=&fulltext=Hexahydrocannabinol&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT
Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus (abst–2005) http://www.sciencedirect.com/science/article/pii/S0028390805001668
Withdrawal Phenomena and Dependence Syndrome After the Consumption of “Spice Gold” (full-2009) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719097/?tool=pmcentrez
Spice drugs: cannabinoids as a new designer drugs (abst–2009) http://www.unboundmedicine.com/medline/ebm/record/19718488/abstract/%5BSpice_drugs:_cannabinoids_as_a_new_designer_drugs_%5D
Spice: a never ending story? (abst–2009) http://www.ncbi.nlm.nih.gov/pubmed/19589652


CP-50,556-1 / LEVONANTRADOL
Clinical experience with levonantradol hydrochloride in the prevention of cancer chemotherapy-induced nausea and vomiting (abst–1981) http://www.ncbi.nlm.nih.gov/pubmed/7298877
Randomised Clinical Trial of Levonantradol and Chlorpromazine in the Prevention of Radiotherapy-induced Vomiting (abst-1982) http://www.ncbi.nlm.nih.gov/pubmed/6754212
Levonantradol, a new antiemetic with a high rate of side-effects for the prevention of nausea and vomiting in patients receiving cancer chemotherapy (abst–1982) http://www.ncbi.nlm.nih.gov/pubmed/7139853
Respiratory and cardiovascular depressant effects of nabilone, N-methyllevonantradol and delta 9-tetrahydrocannabinol in anesthetized cats (abst–1983) http://jpet.aspetjournals.org/content/227/2/508.abstract?maxtoshow=&hits=80&RESULTFORMAT=&fulltext=marihuana&searchid=1&FIRSTINDEX=1920&resourcetype=HWCIT
Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional anti-emetic therapy (abst–1983) http://www.ncbi.nlm.nih.gov/pubmed/6309451
top
Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting (abst–1985) http://www.ncbi.nlm.nih.gov/pubmed/2981616
Thujone exhibits low affinity for cannabinoid receptors but fails to evoke cannabimimetic responses (abst–1999) http://www.ncbi.nlm.nih.gov/pubmed/10080239
Behaviroal, pharmacological, and molecular characterization of an amphibian cannabinoid receptor (full–2000) http://onlinelibrary.wiley.com/doi/10.1046/j.1471-4159.2000.0750413.x/full
Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A (full–2001) http://www.nature.com/npp/journal/v24/n2/full/1395605a.html


CP-55,940
Molecular cloning of a human cannabinoid receptor which is also expressed in testis (full–1991) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1151556/
Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism (full-1992) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1907498/?tool=pmcentrez&page=1
Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, WIN 55,212-2 and anandamide (full-1993) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2175863/?tool=pmcentrez&page=1
Cannabinoids enhance human B-cell growth at low nanomolar concentrations (abst–1995) http://www.ncbi.nlm.nih.gov/pubmed/7544292
AM630, a competitive cannabinoid receptor antagonist (abst–1995) http://www.ncbi.nlm.nih.gov/pubmed/7776818
Involvement of Dynorphin B in the Antinociceptive Effects of the Cannabinoid CP55,940 in the Spinal Cord (full-1997) http://jpet.aspetjournals.org/content/281/2/730.full
Cannabinoid Receptor Agonists Protect Cultured Rat Hippocampal Neurons from Excitotoxicity (full-1998) http://molpharm.aspetjournals.org/content/54/3/459.full
Potent Effects of a Selective Cannabinoid Receptor Agonist on Some Guinea Pig Medial Vestibular Nucleus Neurons (abst–1998) http://www.ncbi.nlm.nih.gov/pubmed/9650841
The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats (abst-1999) http://www.ncbi.nlm.nih.gov/pubmed/10611417
Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human (full-2000) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1571997/?tool=pmcentrez
Behaviroal, pharmacological, and molecular characterization of an amphibian cannabinoid receptor (full–2000) http://onlinelibrary.wiley.com/doi/10.1046/j.1471-4159.2000.0750413.x/full
top
Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation (full-2001) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1572987/?tool=pmcentrez
Protective effects of cannabinoid receptor ligands analogous to anandamide against cocaine toxicity (abst–2001) http://www.ncbi.nlm.nih.gov/pubmed/11828716
Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters (abst-2001) http://www.ncbi.nlm.nih.gov/pubmed/11566149
The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids (full–2002) http://jpet.aspetjournals.org/content/300/1/34.long
Chronic Morphine Modulates the Contents of the Endocannabinoid, 2-Arachidonoyl Glycerol, in Rat Brain (full-2003) http://www.nature.com/npp/journal/v28/n6/full/1300117a.html
Inhibition of guinea-pig and human sensory nerve activity and the cough reflex in guinea-pigs by cannabinoid (CB2) receptor activation (full-2003) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1574031/?tool=pubmed
CANNABINOIDS ALTER RECOGNITION MEMORY IN RATS (full–2003) http://www.if-pan.krakow.pl/pjp/pdf/2003/5_903.pdf
Synergistic Interactions between Cannabinoids and Environmental Stress in the Activation of the Central Amygdala (full-2005) http://www.nature.com/npp/journal/v30/n3/full/1300535a.html
Avoidance of Abeta[(25-35)] / (H(2)O(2)) -induced apoptosis in lymphocytes by the cannabinoid agonists CP55,940 and JWH-015 via receptor-independent and PI3K-dependent mechanisms: role of NF-kappaB and p53 (abst–2005) http://www.ncbi.nlm.nih.gov/pubmed/17017986
Binding affinity and agonist activity of putative endogenous cannabinoids at the human neocortical CB1 receptor (abst–2005) http://www.ncbi.nlm.nih.gov/pubmed/15588725
Effects of repeated administration with CP-55,940, a cannabinoid CB1 receptor agonist on the metabolism of the hepatic heme (abst–2005) http://www.ncbi.nlm.nih.gov/pubmed/15896668
Endocannabinoids — The Brain’s Cannabis – Demonstrate Novel Modes Of Action To Stress (news-2005) http://www.sciencedaily.com/releases/2005/07/050720065810.htm
Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor (full–2006) http://molpharm.aspetjournals.org/content/70/1/41.long
Chronologically overlapping occurrences of nicotine-induced anxiety- and depression-related behavioral symptoms: effects of anxiolytic and cannabinoid drugs (full-2007) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2075518/?tool=pubmed
Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors (full-2007) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2189718/?tool=pubmed
The orphan receptor GPR55 is a novel cannabinoid receptor (full–2007) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095107/?tool=pubmed
Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision (full–2007) http://journals.lww.com/anesthesiology/Fulltext/2007/04000/Spinal_Cannabinoid_Receptor_Type_2_Activation.21.aspx
Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells (full–2007) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2042924/?tool=pubmed
top
CB2 receptors in the brain: role in central immune function (full–2007) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2219530/?tool=pmcentrez
Characterization of cannabinoid-binding sites in zebrafish brain (abst–2007) http://www.frontiersin.org/publications/17178193
Cannabinoids enhance gastric X/A-like cells activity (full–2008) http://czasopisma.viamedica.pl/fhc/article/view/4436/3691
Attenuation of Experimental Autoimmune Hepatitis by Exogenous and Endogenous Cannabinoids: Involvement of Regulatory T Cells (full–2008) http://molpharm.aspetjournals.org/content/74/1/20.full?maxtoshow=&hits=80&RESULTFORMAT=&fulltext=cannabinoid&searchid=1&FIRSTINDEX=320&resourcetype=HWCIT#content-block
Cannabinoids Inhibit HIV-1 Gp120-Mediated Insults in Brain Microvascular Endothelial Cells (full–2008) http://www.jimmunol.org/cgi/content/full/181/9/6406?maxtoshow=&hits=80&RESULTFORMAT=&fulltext=cannabinoid&searchid=1&FIRSTINDEX=160&resourcetype=HWCIT
Activation of cannabinoid receptors prevents antigen-induced asthma-like reaction in guinea pigs (full–2008) http://onlinelibrary.wiley.com/doi/10.1111/j.1582-4934.2008.00258.x/full
The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: implications in Parkinson’s disease (abst-2008) http://www.ncbi.nlm.nih.gov/pubmed/18538428
Evaluation of Delta9 –Tetrahydrocannabinol and other Cannabinoids for Antidepressant-like Actions in the Mouse Forced Swim Test (abst–2008) https://www.thieme-connect.com/ejournals/abstract/10.1055/s-2008-1075224
Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder (abst-2009) http://www.ncbi.nlm.nih.gov/pubmed/19237169
Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin (abst–2009) http://www.ncbi.nlm.nih.gov/pubmed/17397826
top


CRA-13
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration (abst–2007) http://www.ncbi.nlm.nih.gov/pubmed/17630726?dopt=Abstract
Cannabinoid Receptor Agonist 13, a Novel Cannabinoid Agonist: First in Human Pharmacokinetics and Safety (full–2009) http://dmd.aspetjournals.org/content/37/4/827.full
Intestinal lymphatic transport enhances the post-prandial oral bioavailability of a novel cannabinoid receptor agonist via avoidance of first-pass metabolism (abst–2009) http://www.ncbi.nlm.nih.gov/pubmed/19280324
top


ELMIRIC ACIDS
The elmiric acids: biologically active anandamide analogs (full–2007) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2621443/?tool=pmcentrez
Potential anti-inflammatory actions of the elmiric (lipoamino) acids (full–2007) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1896102/?tool=pmcentrez
The elmiric acids: biologically active anandamide analogs (full-2008) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2621443/?tool=pmcentrez
Cannabinoids, Endocannabinoids, and Related Analogs in Inflammation (full–2009) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2664885/?tool=pubmedA


GW-405833
Intrathecal injection of a Cannabinoid CB2 Receptor Selective Agonist GW405833 Blocks Induction of Allodynia by Sciatic Inflammatory Neuritis (SIN) (abst–2009) http://www.efic-congress.org/showabstract.php?abstract=166


GW-833972A
Inhibitory activity of the novel CB2 receptor agonist, GW833972A, on guinea-pig and human sensory nerve function in the airways (full–2008) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2579660/
top


HEXAHYDROCANNABINOLS
Hexahydrocannabinols, novel synthetic cannabinoid derivatives, suppress the tumor growth by inhibiting the VEGF secretion and angiogenesis (abst–2009) http://www.fasebj.org/cgi/content/meeting_abstract/23/1_MeetingAbstracts/761.3?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=cannabis&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT


HU-210
Learning impairment produced in rats by the cannabinoid agonist HU 210 in a water-maze task (abst–1999) http://www.ncbi.nlm.nih.gov/pubmed/10548271
Suppression of Nerve Growth Factor Trk Receptors and Prolactin Receptors by Endocannabinoids Leads to Inhibition of Human Breast and Prostate Cancer Cell Proliferation (full-2000) http://press.endocrine.org/doi/full/10.1210/endo.141.1.7239?view=long&pmid=10614630
Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human (full–2000) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1571997/?tool=pmcentrez
Involvement of central and peripheral cannabinoid receptors in the regulation of heart resistance to arrhythmogenic effects of epinephrine (abst–2000) http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Retrieve&list_uids=11182823&dopt=abstractplus
Inhibitory effects of the cannabinoid agonist HU 210 on rat sexual behaviour (abst–2000) http://www.ncbi.nlm.nih.gov/pubmed/10913795
Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease (full–2002) http://bloodjournal.hematologylibrary.org/cgi/content/full/100/2/627?ijkey=eb71d6d7a06f311440761cfac6a7d081bcc2771d
Influence of the CB1 receptor antagonist, AM 251, on the regional haemodynamic effects of WIN-55212-2 or HU 210 in conscious rats (full-2002) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1573379/?tool=pmcentrez
Activation of cannabinoid receptors decreases the area of ischemic myocardial necrosis (abst–2002) http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Retrieve&list_uids=12428278&dopt=abstractplus
Increase of the heart arrhythmogenic resistance and decrease of the myocardial necrosis zone during activation of cannabinoid receptors (abst–2002) http://www.ncbi.nlm.nih.gov/pubmed/12136723
The cannabinoids R(-)-7-hydroxy-delta-6-tetra-hydrocannabinol-dimethylheptyl (HU-210), 2-O-arachidonoylglycerylether (HU-310) and arachidonyl-2-chloroethylamide (ACEA) increase isoflurane provoked sleep duration by activation of cannabinoids 1 (CB1)-receptors in mice (abst–2002) http://www.ncbi.nlm.nih.gov/pubmed/12095655
top
Inhibition of tumor angiogenesis by cannabinoids (full–2003) http://www.fasebj.org/cgi/reprint/02-0795fjev1?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=cannabis&andorexactfulltext=and&searchid=1&FIRSTINDEX=20&sortspec=relevance&resourcetype=HWCIT
CB1 cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction (full-2003) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1573770/?tool=pmcentrez
Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210 (full-2003) http://stroke.ahajournals.org/cgi/reprint/34/8/2000
Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin (abst–2003) http://www.ncbi.nlm.nih.gov/pubmed/12835895
The endogenous cannabinoid system protects against colonic inflammation (full–2004) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC385396/?tool=pmcentrez
Cannabinoids spell relief in colon inflammation (news–2004) http://www.mpg.de/496761/pressRelease20040506?filter_order=L
Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects (full-2005) http://www.jci.org/articles/view/25509/version/1
Direct cerebrovascular effects of CB1 receptor activation by the synthetic endocannabinoid HU-210 in vivo (abst-2005) http://www.nature.com/jcbfm/journal/v25/n1s/full/9591524.0581a.html
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease (abst-2005) http://www.ncbi.nlm.nih.gov/pubmed/15837565?dopt=Abstract
The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors (abst–2005) http://www.sciencedirect.com/science/article/pii/S0014299905013178
Is cannabis good for your brain? (news-2005) http://arstechnica.com/science/news/2005/10/1529.ars
Study Shows Marijuana Promotes Neuron Growth (news–2005) http://english.ohmynews.com/articleview/article_view.asp?menu=c10400&no=253377&rel_no=1
Marijuana May Grow Neurons in the Brain (news–2005) http://www.medpagetoday.com/Psychiatry/AnxietyStress/1934
Surprising Brain Effects From Pot-Like Drug (news–2005) http://www.webmd.com/mental-health/news/20051013/surprising-brain-effects-from-pot-like-drug
Marijuana might cause new cell growth in the brain (news–2005) (may need registration) http://www.newscientist.com/article/dn8155
Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models (full-2006) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1751298/?tool=pmcentrez
Arthritis and cannabinoids: HU-210 and Win-55,212-2 prevent IL-1alpha-induced matrix degradation in bovine articular chondrocytes in-vitro (abst-2006) http://www.ncbi.nlm.nih.gov/pubmed/16536902
Cannabinoids Ameliorate Pain and Reduce Disease Pathology in Cerulein-Induced Acute Pancreatitis (full-2007) http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2268094
top
Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon (full-2007) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2755791/?tool=pmcentrez
Actions of N-arachidonyl-glycine in a rat inflammatory pain model (full–2007) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2042976/
Cannabinoids Induce Glioma Stem-like Cell Differentiation and Inhibit Gliomagenesis (full-2007) http://www.jbc.org/content/282/9/6854.long
The synthetic cannabinoid HU210 induces spatial memory deficits and suppresses hippocampal firing rate in rats (full–2007) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2013991/
The synthetic cannabinoid HU-210 attenuates neural damage in diabetic mice and hyperglycemic pheochromocytoma PC12 cells (abst-2007) http://www.ncbi.nlm.nih.gov/pubmed/17604177
The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain (abst–2007) http://www.ncbi.nlm.nih.gov/pubmed/17572451
Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation (abst–2007) http://www.ncbi.nlm.nih.gov/pubmed/17229577
Characterization of cannabinoid-binding sites in zebrafish brain (abst–2007) http://www.frontiersin.org/publications/17178193
Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death (abst–2007) http://www.ncbi.nlm.nih.gov/pubmed/17931597
Repeated Cannabinoid Injections into the Rat Periaqueductal Gray Enhances Subsequent Morphine Antinociception (full-2008) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743428/?tool=pmcentrez
Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma (full-2009) http://mct.aacrjournals.org/content/8/7/1838.full
Lipid rafts regulate 2-arachidonoylglycerol metabolism and physiological activity in the striatum (full–2009) http://onlinelibrary.wiley.com/doi/10.1111/j.1471-4159.2009.05948.x/full
Cannabinoid receptor activation reverses kainate-induced synchronized population burst firing in rat hippocampus (abst–2009) http://www.frontiersin.org/integrative_neuroscience/10.3389/neuro.07.013.2009/abstract
Spice drugs: cannabinoids as a new designer drugs (abst–2009) http://www.unboundmedicine.com/medline/ebm/record/19718488/abstract/%5BSpice_drugs:_cannabinoids_as_a_new_designer_drugs_%5D
top


HU-211
A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat (abst–1993) http://www.ncbi.nlm.nih.gov/pubmed/8411215
HU-211, a Novel Noncompetitive N-Methyl-D-Aspartate Antagonist, Improves Neurological Deficit and Reduces Infarct Volume After Reversible Focal Cerebral Ischemia in the Rat (full-1995) http://stroke.ahajournals.org/cgi/content/full/26/12/2313
45Ca accumulation in rat brain after closed head injury; attenuation by the novel neuroprotective agent HU-211 (abst–1995) http://www.ncbi.nlm.nih.gov/pubmed/7583233
Development of HU-211 as a neuroprotectant for ischemic brain damage (abst – 1995) http://www.ncbi.nlm.nih.gov/pubmed/7477742
A novel nonpsychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis (full-1996) http://jid.oxfordjournals.org/content/173/3/735.long
HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy (abst–1996) http://www.ncbi.nlm.nih.gov/pubmed/8714863
Protection Against Septic Shock and Suppression of Tumor Necrosis Factor α and Nitric Oxide Production by Dexanabinol (HU-211), a Nonpsychotropic Cannabinoid (full-1997) http://jpet.aspetjournals.org/content/283/2/918.full
Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant (abst–1997) http://www.ncbi.nlm.nih.gov/pubmed/9042110
Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia (abst–1999) http://www.ncbi.nlm.nih.gov/pubmed/10202976
Cannabinoids in clinical practice (abst-2000) http://www.ncbi.nlm.nih.gov/pubmed/11152013
Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial (abst-2002) http://www.ncbi.nlm.nih.gov/pubmed/11990913?dopt=Abstract
Dexanabinol: a novel cannabinoid with neuroprotective properties (abst–2003) http://www.ncbi.nlm.nih.gov/pubmed/14534855
Dexanabinol (HU-211) has a beneficial effect on axonal sprouting and survival after rat optic nerve crush injury (abst–2003) http://www.ncbi.nlm.nih.gov/pubmed/12535983
Therapeutic potential of cannabinoids in CNS disease (abst–2003) http://www.ncbi.nlm.nih.gov/pubmed/12617697
Dexanabinol: dexanabinone, HU 211, PA 50211, PRS 211007, sinnabidol (abst-2003) http://www.ncbi.nlm.nih.gov/pubmed/12757406
Dexanabinol prevents development of vasospasm in the rat femoral artery model (abst–2008) http://www.ncbi.nlm.nih.gov/pubmed/18256864
top


HU-308
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor (full–1999) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC24419/?tool=pubmed
Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation (full–2005) http://www.fasebj.org/cgi/content/full/20/13/2405?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=cannabis&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT
Peripheral cannabinoid receptor, CB2, regulates bone mass (full–2005) http://www.pnas.org/content/103/3/696.full
Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain (abst-2005) http://www.ncbi.nlm.nih.gov/pubmed/16316653
Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation (full–2006) http://www.fasebj.org/content/20/13/2405.long
Activation of CB2 receptor attenuates bone loss in osteoporosis (news–2006) http://www.cannabis-med.org/english/bulletin/ww_en_db_cannabis_artikel.php?id=210#2
Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis (full-2007) http://www.jleukbio.org/cgi/content/full/82/6/1382
Endocannabinoids, cannabinoid receptors and inflammatory stress: an interview with Dr. Pál Pacher (interview–2007) http://www.jleukbio.org/cgi/content/full/82/6/1390?maxtoshow=&hits=80&RESULTFORMAT=&fulltext=cannabinoid&searchid=1&FIRSTINDEX=880&resourcetype=HWCIT
Regulation of Bone Mass, Osteoclast Function, and Ovariectomy-Induced Bone Loss by the Type 2 Cannabinoid Receptor (full–2008) http://press.endocrine.org/doi/full/10.1210/en.2008-0150


HU-310
Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB(1) receptor-dependent G-protein activation in rat cerebellar membranes (full–2001) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1572991/
The cannabinoids R(-)-7-hydroxy-delta-6-tetra-hydrocannabinol-dimethylheptyl (HU-210), 2-O-arachidonoylglycerylether (HU-310) and arachidonyl-2-chloroethylamide (ACEA) increase isoflurane provoked sleep duration by activation of cannabinoids 1 (CB1)-receptors in mice (abst–2002) http://www.ncbi.nlm.nih.gov/pubmed/12095655
top


HU-320
A novel synthetic, non-psychoactive cannabinoid acid (HU-320) with anti-inflammatory properties in murine collagen-induced arthritis (full-2004) http://onlinelibrary.wiley.com/doi/10.1002/art.20050/full
HU-320 identified as a novel synthetic cannabinoid with therapeutic activity in an experiment model of rheumatoid arthritis (news–2004) http://www.hospitalpharma.com/features/feature.asp?ROW_ID=405


HU-331
A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells (full-2006) http://molpharm.aspetjournals.org/content/70/1/51.long
A Cannabinoid Anticancer Quinone, HU-331, Is More Potent and Less Cardiotoxic Than Doxorubicin: A Comparative in Vivo Study (full-2007) http://jpet.aspetjournals.org/content/322/2/646.full
HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor (full–2007) http://mct.aacrjournals.org/content/6/1/173.long
HU-331: a cannabinoid quinone, with uncommon cytotoxic properties and low toxicity (abst-2007) http://www.ncbi.nlm.nih.gov/pubmed/17714026
Antitumorigenic Effects of Cannabinoids beyond Apoptosis (full–2010) http://jpet.aspetjournals.org/content/332/2/336.full?sid=af53ea87-ab4b-426e-9c7e-8f750e9c4a17
HU-331: a cannabinoid quinone, with uncommon cytotoxic properties and low toxicity (abst-2007) http://www.ncbi.nlm.nih.gov/pubmed/17714026
top